Department of Endocrinology, St. John's National Academy of Health Sciences, Bangalore 560034, Karnataka, India.
Med Clin North Am. 2013 Sep;97(5):857-72. doi: 10.1016/j.mcna.2013.05.002.
The Charcot foot is a problematic clinical entity that worsens in the absence of timely intervention. As of now, based on the ADA consensus report, offloading with TCC continues to remain the mainstay of therapy for CN.1 A standardized approach to the management of CN is depicted in Fig. 1. Furthermore, ongoing inflammatory activity can be controlled with antiresorptive agents, like BPPs and calcitonin; however, data acquired from larger trials with these agents are awaited. Newer agents that target the inflammatory cascade have been identified and applied in limited clinical trials in non-Charcot conditions. Their potential role in the future management of CN has yet to be established.
夏科氏足是一种临床问题，若不及时干预，病情会恶化。目前，根据 ADA 共识报告，使用 TCC 减压仍然是 CN 治疗的主要方法。图 1 描述了 CN 管理的标准化方法。此外，还可以使用抗吸收剂（如 BPP 和降钙素）控制持续的炎症活动，但仍需要等待这些药物的更大规模试验数据。已经确定了针对炎症级联反应的新型药物，并在非夏科氏病的有限临床试验中应用。它们在 CN 未来治疗中的潜在作用尚未确定。
